GSK’s oncology portfolio is key to growth prospects, as they are expected to offset headwinds currently faced in HIV and the Advair business.

Zejula provided additional data in maintenance treatment of ovarian cancer that could present share gain opportunities from Lynparza. GSK will look to expand Zejula into additional oncology indications.

Belantamab mafodotin could be the first to market within the BCMA class of drugs in multiple myeloma, and will provide additional details at ASH in early December along with other BCMA treatments.